Compounds > 3mb-pp1
Page last updated: 2024-11-13

3mb-pp1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID24865390
CHEMBL ID1236661
SCHEMBL ID12436052
MeSH IDM0588943

Synonyms (33)

Synonym
CHEMBL1236661
vgg ,
1-tert-butyl-3-(3-methylbenzyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine
DB08699
FT-0661637
4LGG
956025-83-5
4-amino-1-tert-butyl-3-(3-methylbenzyl)pyrazolo[3,4-d]pyrimidine
2WEI
W-204130
4-amino-1-tert-butyl-(3-methylbenzyl)pyrazolo[3,4-d]pyrimidine
SCHEMBL12436052
3mb-pp1
1-(tert-butyl)-3-(3-methylbenzyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine
AC-26930
3-mb-pp1
AKOS025401891
DTXSID20647754
1-tert-butyl-3-[(3-methylphenyl)methyl]-1h-pyrazolo[3,4-d]pyrimidin-4-amine
4-amino-1-t-butyl-3-(3-methylbenzyl)pyrazolo[3,4-d]pyrimidine
Q27097886
LP62329LQ7 ,
1-tert-butyl-3-((3-methylphenyl)methyl)pyrazolo(3,4-d)pyrimidin-4-amine
unii-lp62329lq7
1h-pyrazolo(3,4-d)pyrimidin-4-amine, 1-(1,1-dimethylethyl)-3-((3-methylphenyl)methyl)-
1-(1,1-dimethylethyl)-3-[(3-methylphenyl)methyl]-1h-pyrazolo[3,4-d]pyrimidin-4-amine
MS-24230
1-tert-butyl-3-[(3-methylphenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-amine
HY-102069
A846880
CS-0022947
PD004201
1h-pyrazolo[3,4-d]pyrimidin-4-amine,1-(1,1-dimethylethyl)-3-[(3-methylphenyl)methyl]-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CALMODULIN-DOMAIN PROTEIN KINASE 1, PUTATIVECryptosporidium parvum Iowa IIIC50 (µMol)0.00340.00340.00340.0034AID977608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1604321Antiparasitic activity against Toxoplasma gondii2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.
AID728287Selectivity ratio of IC50 for Toxoplasma gondii RH CDPK1 G128S mutant to Toxoplasma gondii RH full length CDPK12013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728294Antiparasitic activity against wild type tachyzoites of Toxoplasma gondii RH type 1 infected in HFF cells incubated for 20 mins prior to inoculation followed by compound washout at 4 hrs measured after 72 hrs by beta-galactoside reporter assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728285Ratio of growth inhibition of Toxoplasma gondii harboring wild type CDPK1 to growth inhibition of Toxoplasma gondii harboring CDPK1 G128M mutant2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728295Inhibition of Toxoplasma gondii RH full length CDPK1 expressed in Escherichia coli BL21(DE3) using syntide-2 peptide as substrate after 20 mins by ELISA2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728282Antiparasitic activity against trachyzoites of Toxoplasma gondii type 2 expressing Pru-LUC infected in Balb/c mouse assessed as host survival at 5 mg/kg, iv administered for 10 days measured on day 302013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728286Antiparasitic activity against Toxoplasma gondii harboring wild type CDPK1 infected in HFF cells incubated for 20 mins prior to infection followed by compound washout at 1 hr measured after 72 hrs by crystal violet staining method2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728297Antiparasitic activity against tachyzoites of Toxoplasma gondii RH type 1 infected in HFF cells incubated for 4 hrs followed by compound washout measured after 72 hrs by beta-galactoside reporter assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID1604320Inhibition of Toxoplasma gondii CDPK12019European journal of medicinal chemistry, Dec-01, Volume: 183Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.
AID728288Selectivity ratio of IC50 for Toxoplasma gondii RH CDPK1 G128A mutant to Toxoplasma gondii RH full length CDPK12013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID728281Antiparasitic activity against Toxoplasma gondii type 2 expressing Pru-LUC infected in Balb/c mouse assessed reduction in number of tissue cysts in brain at 5 mg/kg, iv administered for 10 days measured after 30 days by fluorescently labeled lectin staini2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2013ACS chemical biology, Sep-20, Volume: 8, Issue:9
Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2011BMC genomics, Sep-30, Volume: 12The Cryptosporidium parvum kinome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.54 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		3.3110hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		3.3110benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
1-NA-PP1
[no description available]		2.0810pyrazolopyrimidinetyrosine kinase inhibitor
pyrimethamine
Maloprim: contains above 2 cpds		2.0810aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
oleanolic acid
[no description available]		3.3110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
ursolic acid
[no description available]		3.3110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
buparvaquone
buparvaquone: used in therapy of theileriasis; structure given in first source		3.3110
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		2.1510
oleanolic acid 3-acetate
oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer		3.3110
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		3.3110abietane diterpenoid
halofuginone
[no description available]		3.3110
tamoxifen
[no description available]		3.3110stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine
[no description available]		2.4920pyrazolopyrimidinetyrosine kinase inhibitor
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		3.3110chalcones
guttiferone e
guttiferone E: isolated from the fruits of Garcinia pyrifera collected in Malaysia; structure in first source		3.3110
3 beta-o-acetylursolic acid
[no description available]		3.3110triterpenoid
jasplakinolide
jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R*,4E,6S*,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.		3.3110cyclodepsipeptide;
phenols		actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
nitd 609
NITD 609: an antimalarial and coccidiostat; structure in first source		3.3110
zaprinast
zaprinast: anaphylaxis inhibitor; structure		3.3110triazolopyrimidines
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0810
Infection, Toxoplasma gondii
[description not available]		03.4520
Toxoplasmosis
The acquired form of infection by Toxoplasma gondii in animals and man.		03.4520
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.1210